Speaker: Olga Morozova, Ph.D.

Title: Treatment of opioid use in disorder in the context of the war in Ukraine: Trial of injectable depot buprenorphine

Introduction: Dr. Morozova is an epidemiologist with research interests at the intersection of substance use disorders, infectious diseases and other mental health conditions. Originally from Ukraine, Dr. Morozova conducted studies to evaluate strategies to expand access to and uptake of opioid agonist treatment in Ukraine. She piloted studies of primary healthcare-based integrated care for people with opioid use disorder in Ukraine and conducted model-based policy and cost-effectiveness evaluation of treatment scale-up strategies. Some of her recent studies include piloting extended-release buprenorphine in Ukraine, investigating HIV pre-exposure prophylaxis adherence among people who inject drugs, estimating prevalence of mental health conditions among patients with opioid use disorder in Ukraine and assessing the efficacy of preventing viral rebound among patients receiving different ART regimens. She currently serves as an MPI on a NIDA-funded study that investigates the effects of war-related trauma on HIV care engagement among people with a history of substance use disorders in Ukraine.
Dr. Morozova earned her Ph.D. degree in Epidemiology from Yale School of Public Health and completed her postdoctoral training at Yale Biostatistics. She received her M.S. degree in Mathematical Modeling in Social Sciences and B.S. degree in Applied Mathematics from the National University of Kyiv, Ukraine.

Learning Objectives: 
Upon completion of this activity, participants should be able to:

1. Describe the impact of the armed conflict in Ukraine on opioid agonist therapy (OAT) delivery and summarize the strategies Ukraine implemented to sustain treatment access during an active armed conflict.
2. Summarize the enrollment, 12-month retention, and discontinuation outcomes from the first real-world trial of extended-release buprenorphine (BUP-XR) in a middle-income country and differentiate the clinical and behavioral correlates associated with the two main reasons for BUP-XR discontinuation.
3. Examine patient populations and clinical contexts in which BUP-XR may offer advantages over daily sublingual buprenorphine and discuss how contextual factors- including take-home dosing availability and initial dose selection – influence real-world BUP-XR uptake and retention.

ATTENDANCE / CREDIT
Text the session code (provided only at the session) to 507-200-3010 within 48 hours of the live presentation to record attendance. All learners are encouraged to text attendance regardless of credit needs. This number is only used for receiving text messages related to tracking attendance. Additional tasks to obtain credit may be required based on the specific activity requirements and will be announced accordingly. Swiping your badge will not provide credit; that process is only applicable to meet GME requirements for Residents & Fellows.

TRANSCRIPT
Any credit or attendance awarded from this session will appear on your Transcript.

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) and staff, please go here to review disclosures.